Research Article
Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
Table 6
Predictors of significant (>5%) decrease of glycemia after DAA treatment.
| | | Glycemia 5% decrease not achieved
(mean±SEM or absolute (relative) counts | Glycemia 5% decrease achieved
(mean±SEM or absolute (relative) counts | P | OR | 95%CI |
| | Age (years) | 60±1 | 61±1 | 0.303 | 1.01 | 0.97-1.04 |
| | Male sex | 43 (45.3) | 25 (30.5) | 0.044 | 0.53 | 0.26-0.99 |
| | BMI (kg/m2) | 26.9±0.46 | 27.2±0.44 | 0.807 | 1.015 | 0.93-1.10 |
| | HCV RNA (IU/mL) | 2 380 969±443 997 | 3 404 197±595 764 | 0.092 | 1.369 | 0.91-2.06 |
| | Treatment experienced | 72 (75.8) | 66 (80.5) | 0.452 | 1.32 | 0.64-2.71 |
| | Elastography (kPa) | 9.6±1.23 | 11.1±1.41 | 0.849 | 1.01 | 0.98-1.04 |
| | F4 fibrosis (elastography) | 45 (47.4) | 44 (55.0) | 0.363 | 1.43 | 0.66-3.12 |
| | F3 fibrosis (elastography) | 28 (29.5) | 21 (26.3) | 0.829 | 1.10 | 0.46-2.62 |
| | Thrombocytes x109/L | 172±7.7 | 157±9.5 | 0.07 | 0.997 | 0.994-1.001 |
| | APRI | 1.43±0.16 | 1.56±0.16 | 0.558 | 1.063 | 0.87-1.31 |
| | Baseline fasting glucose (mmol/L) | 5.7±1.8 | 7.2±2.7 | <0.0001 | 1.431 | 1.177-1.740 |
|
|
